bellus health stock

Currency in USD, Trade prices are not sourced from all markets. 9 Wall Street analysts have issued ratings and price targets for BELLUS Health in the last 12 months. The company’s stock price has collected 11.81% of gains in the last five trading sessions. BELLUS Health Inc. (NASDAQ:BLU) went up by 11.81% from its latest closing price compared to the recent 1-year high of $12.03. The average price target is C$11.01 with a high forecast of C$12.70 and a low forecast of C$10.16.The average price target represents a 129.36% increase from the last price of C$4.80. BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will participate in two upcoming virtual healthcare investor conferences. The high price target for BLU is $12.00 and the low price target for BLU is $6.00. BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will participate in two upcoming virtual healthcare investor conferences. The newest price gain of Bellus Health could raise concerns from private investors as the firm it trading at a share price of 4.56 on 6,274,952 in volume. View Bellus Health Inc. BLU investment & stock information. Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value , Growth and Safety for BELLUS Health … Stock Chart. A number of research analysts recently issued reports […] The increase is primarily attributable to the Company’s increased workforce in 2020 as well as to higher stock-based compensation expense in relation to BELLUS Health’s stock option plan. Get the latest Bellus Health Inc. BLU detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Do the numbers hold clues to what lies ahead for the stock? Get the latest stock price for BELLUS Health Inc. (BLU), plus the latest news, recent trades, charting, insider activity, and analyst ratings. Get the hottest stocks to trade every day before the market opens 100% free. BELLUS Health Inc (BLU) stock is down -6.36% while the S&P 500 is up 1.99% as of 1:09 PM on Thursday, Jan 28. View today's stock price, news and analysis for BELLUS Health Inc. (BLU). The Macroaxis performance score is an integer between 0 and 100 that represents Bellus's market performance from a risk-adjusted return perspective. View real-time stock prices and stock quotes for a full financial overview. BELLUS Health's stock was trading at $9.40 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Based on 3 analysts offering 12 month price targets for BELLUS Health in the last 3 months. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada. Bellus (BLU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. The company’s stock has been forecasted to trade at an average price of $7.32 over the course of the next 52 weeks, with a low of $2.6 and a high of $12. Data Provided by Refinitiv. Find the latest BELLUS HEALTH INC. (BLU.TO) stock quote, history, news and other vital information to help you with your stock trading and investing. Bellus Health Tumbles On Failed Midstage Study Of Lead Drug. What's Happening With BELLUS Health Inc Stock Today? Press Release reported 10 hours ago that IIROC Trade Resumption – BLU. The company traded as low as $3.31 and last traded at $3.38. BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Volume today is 957,154 compared to average volume of 1,167,403. BELLUS Health (NASDAQ:BLU) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Tuesday, Zacks.com reports. Canadian biopharma BELLUS Health Inc (NASDAQ: BLU) was losing about three-fourths of its value in … Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus. BELLUS HEALTH INC 0A4U Overview - Search stock, chart, recent trades, company information, trading information, company news, fundamentals Change Volume Today's Open Previous Close. Get the latest BELLUS Health Inc. (BLU) stock news and headlines to help you in your trading and investing decisions. Real time BELLUS Health Inc. (BLU) stock price quote, stock graph, news & analysis. Post-Market 0.02 (0.50%) Stock analysis on safety metrics: The higher the rank, the lower the leverage of BELLUS Health and the more cash is available to service its debt. In 2020, BELLUS Health's revenue was 15,000, a decrease of -44.44% compared to the previous year's 27,000. Since then, BLU shares have decreased by 57.1% and is now trading at $4.03. Today's High Today's Low 52 Week High 52 Week Low. The stock had previously closed at $3.69. According to Zacks, “BELLUS Health is a global health company focused on the development and commercialization of products to provide innovative health solutions to address critical unmet medical needs. As of late, it has definitely been a great time to be an investor in BELLUS Health. The company's lead drug has failed a phase 2 trial. Shares of Bellus Health were falling 69.2% at 2:40 p.m. EST on Monday following its announcement that a phase 2 trial of BLU-5937 as a treatment for refractory chronic cough has missed its … BELLUS Health Inc. (NASDAQ:BLU) shares fell 8.4% on Wednesday . 1,561,409 shares changed hands during trading, an increase of 24% from the average session volume of 1,255,318 shares. BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today reported its financial and operating results for the year ending December 31, 2020. The company's lead drug has failed a phase 2 trial.

Cartoon Network Invaded Dvd, Mr And Mrs Movie, Singapore Export Products, Cheerleader Competition In Orlando Florida, Hall High School Athletics, Daily Herald Delivery Problem,